TP53 and neoplasm: Previous reports have documented the prevalence of both germline and somatic ATM mutations in DLBCL, suggesting a role for the ARF-TP53 pathway as a tumor suppressor in this disease [29], as well as the prognostic impact of TP53 hotspot mutations [30].